Evaluation of Galantamine in the Treatment of Alzheimer's Disease
NCT ID: NCT00000172
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Galantamine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mini-Mental State Examination (MMSE) 10-22 and ADAS greater than or equal to 18
* Alzheimer's Disease Assessment Scale cognitive portion (ADAS-cog-11) score of at least 18
* Opportunity for Activities of Daily Living
* Caregiver
* Subjects who live with or have regular daily visits from a responsible caregiver (visit frequency: preferably daily but at least 5 days/week). This includes a friend or relative or paid personnel. The caregiver should be capable of assisting with the subject's medication, prepared to attend with the subject for assessments, and willing to provide information about the subject.
Exclusion Criteria
* Neurodegenerative disorders
* Acute cerebral trauma
* Psychiatric disease
* More than one infarct on CT/MRI scans
* History of alcohol or drug abuse
* Contradictions for a cholinominetic agent: seizures; ulcers; pulmonary conditions (including severe asthma); unstable angina; Afib; bradycardia less than 50; and AV block.
0 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen, LP
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama, Birmingham
Birmingham, Alabama, United States
James L. Frey, M.D., Ltd.
Scottsdale, Arizona, United States
East Bay Neurology
Berkeley, California, United States
University of Southern California
Los Angeles, California, United States
N. County Neurology Assoc.
Oceanside, California, United States
University of California Irvine Medical Center
Orange, California, United States
Pacific Research Network (PRN)
San Diego, California, United States
Affiliated Research Institute
San Diego, California, United States
INC
San Diego, California, United States
The Denver Center for Medical Research
Denver, Colorado, United States
Geriatric and Adult Psychiatry
Hamden, Connecticut, United States
Yale University, School of Medicine
New Haven, Connecticut, United States
Ocala Neurodiagnostic Center
Ocala, Florida, United States
Psychiatric Institute of Florida
Orlando, Florida, United States
Neurological Research Institute of Sarasota, PA
Sarasota, Florida, United States
Suncoast Neuroscience Associates, Inc.
St. Petersburg, Florida, United States
Premiere Research Institute
West Palm Beach, Florida, United States
Chicago Center for Clinical Research
Chicago, Illinois, United States
OSF Center for Senior Health
Peoria, Illinois, United States
Indiana Alzheimer's University Clinic
Indianapolis, Indiana, United States
The Johns Hopkins Hospital
Baltimore, Maryland, United States
Brigham Behavioral Neurology Group
Boston, Massachusetts, United States
Boston Clinical Research Center
Wellesley Hills, Massachusetts, United States
University of Massachusetts Worcester
Worcester, Massachusetts, United States
Oakwood Hospital and Medical Center
Dearborn, Michigan, United States
Michigan Medical P.C.
Grand Rapids, Michigan, United States
Regions Hospital
Saint Paul, Minnesota, United States
St. Louis University School of Medicine
St Louis, Missouri, United States
Washington University
St Louis, Missouri, United States
University of Nebraska
Omaha, Nebraska, United States
University of Medicine and Dentistry of New Jersey
Piscataway, New Jersey, United States
Neurology Group of Bergen County
Ridgewood, New Jersey, United States
Overlook Hospital
Summit, New Jersey, United States
Medwise Center
West Long Branch, New Jersey, United States
Neurological Associates of Albany, PC
Albany, New York, United States
East End Neuropsychiatric Associates
Centereach, New York, United States
St. John's Episcopal Hospital
Far Rockaway, New York, United States
NYU Medical Center
New York, New York, United States
University of Rochester
Rochester, New York, United States
SUNY Stony Brook
Stony Brook, New York, United States
Ohio State University
Columbus, Ohio, United States
Clinical Pharmaceutical Trials
Tulsa, Oklahoma, United States
Oregon Health Sciences University
Portland, Oregon, United States
Pacific NW Clinical Research Center
Portland, Oregon, United States
Institute for Advanced Clinical Research
Elkins Park, Pennsylvania, United States
Neuroscience Center of Westmoreland Neurology
Greensburg, Pennsylvania, United States
Brown University
Pawtucket, Rhode Island, United States
Alzheimer's Research and Clinical Programs
North Charleston, South Carolina, United States
University of Texas
Dallas, Texas, United States
Southwestern Vermont Medical Center
Bennington, Vermont, United States
Memory Disorder Center of Vermont
Colchester, Vermont, United States
Virginia Neuroscience Center
Alexandria, Virginia, United States
Prince William Neuroscience Center
Manassas, Virginia, United States
Seattle Clinical Research Center
Seattle, Washington, United States
VAPS Health Care System
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lilienfeld S, Parys W. Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. doi: 10.1159/000051228.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IA0009
Identifier Type: -
Identifier Source: org_study_id